Zhitong Finance App News, Lingkang Pharmaceutical (603669.SH) issued an announcement. Recently, Hainan Lingkang Pharmaceutical Co., Ltd. (hereinafter referred to as “Lingkang Pharmaceutical”), a wholly-owned subsidiary of the company, received the approval and issuance of the “Drug Registration Certificate” for injectable isaconazole sulfate from the China Drug Administration (hereinafter referred to as the “State Drug Administration”). The company's injectable isaconazole sulfate obtained the “Drug Registration Certificate” from the State Drug Administration, indicating that the company is qualified to manufacture and sell this drug in the domestic market, further enriching the company's product line of anti-infective drugs and helping to enhance the market competitiveness of the company's products.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.